Editorial Commentary: Antiretroviral Therapy: The “When to Start” Debates
Open Access
- 1 December 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (11) , 1705-1708
- https://doi.org/10.1086/425934
Abstract
With the recent approval of several new antiretrovirals and with new research regarding the efficacy and safety of HAART comes a necessary revisiting of the timing of initiation of treatment for HIV infection. This is an important part of the dialogue regarding HIV medicine, and it ensures clinicians are providing, and patients are receiving, the best possible care based on available data.Keywords
This publication has 17 references indexed in Scilit:
- Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIVJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Treatment for Adult HIV InfectionJAMA, 2004
- SOLOAIDS, 2004
- Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infectionAIDS, 2002
- Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/lAIDS, 2002
- Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug TherapyJAMA, 2001
- HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral LoadJAMA, 2001
- When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA studyAIDS, 2001
- Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1New England Journal of Medicine, 2000
- Time to Hit HIV, Early and HardNew England Journal of Medicine, 1995